Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682974 | 0.83 | MEN1 (0.77) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL395744 | 0.83 | MEN1 (0.77) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL1396337 | 0.82 | CYP11B1 (0.53) | MEN1KMT2AMAPT | |
| SCHEMBL31681274 | 0.81 | MEN1 (0.73) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL2692159 | 0.81 | KMT2A (1.00) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL5915295 | 0.81 | MEN1 (1.00) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL16358437 | 0.81 | MEN1 (0.73) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL12053364 | 0.81 | MEN1 (0.73) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL10143525 | 0.80 | MEN1 (0.59) | MEN1KMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL14314105 | 0.80 | POLB (0.54) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086701-A1 | ENANTIOSELECTIVE SYNTHESIS OF PYRROLOINDOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086701-A1 | ENANTIOSELECTIVE SYNTHESIS OF PYRROLOINDOLE COMPOUNDS | PCNA, POLR2E, POLL | MEN1 3599/4885KMT2A 2283/4885ALDH1A1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.